Shots:

• The EUA is based on data from several clinical trials- including P-III trial evaluating REGEN-COV (SC injection or IV infusion) vs PBO in high-risk patients with COVID-19 for post-exposure prophylaxis. The trial is jointly run with the NIAID
• The results showed 81% reduction in the risk of symptomatic infections while 62% reduction in asymptomatic patients based on a post-hoc analysis
• Regeneron collaborates with Roche to increase global supply of the Ab cocktail & Roche is responsible for development and distribution outside the US. REGEN-COV is currently available in 20+ countries including U.S.- EU- India- Switzerland and Canada- and is also fully approved in Japan

 to   | Ref: Regeneron | Image: WRGB